A<unk>  (cyclin-dependent kinase) inhibitor is any chemical that inhibits the function of<unk> s. They are used to treat cancers by preventing overproliferation of cancer cells. The US FDA approved the first drug of this type, palbociclib (Ibrance), a<unk> 4/6 inhibitor, in February 2015, for use in postmenopausal women with breast cancer that is estrogen receptor positive and HER2 negative. Several compounds are in clinical trials.
CDK inhibitor
Histone deacetylase inhibitor
MEK inhibitor
Protein kinase inhibitor
RET inhibitor
COX-2 inhibitor
Topoisomerase inhibitor
Growth factor receptor inhibitor